Does Cosentyx Affect Vaccine Response After Injection?
Cosentyx (secukinumab), an IL-17A inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, impairs immune responses to vaccines administered post-injection. Clinical data show reduced antibody production against pneumococcal, tetanus, and influenza vaccines in patients on Cosentyx compared to placebo.[1][2]
In a phase 3 trial, patients on secukinumab produced fewer protective antibodies to the 23-valent pneumococcal vaccine (PPSV-23): 42-47% achieved titers ≥10 times baseline versus 65% on placebo. Tetanus toxoid responses dropped to 39-47% versus 72% on placebo. Influenza vaccine efficacy was also lower, though less pronounced.[1]
Live vaccines are contraindicated due to immunosuppression risk, but inactivated vaccines show diminished but measurable responses.[2]
How Long Does the Vaccine Impairment Last?
IL-17 inhibition peaks within weeks of Cosentyx dosing (300 mg subcutaneous every 4 weeks after loading). Vaccine studies tested responses 2-4 weeks post-vaccination, aligning with steady-state drug levels. Impairment likely persists during active treatment, with recovery possible 8-12 weeks after discontinuation as secukinumab's half-life is ~27 days.[2][3]
No direct data on exact recovery timelines; clinicians recommend vaccinating before starting Cosentyx or during drug holidays if feasible.[2]
Which Vaccines Are Most Impacted?
| Vaccine Type | Response on Cosentyx | Key Data |
|--------------|-----------------------|----------|
| Pneumococcal (PPSV-23) | Markedly reduced (42-47% responders) | Lowest efficacy in trials[1] |
| Tetanus toxoid | Reduced (39-47%) | Similar to pneumococcal[1] |
| Influenza (inactivated) | Mildly reduced | Protective in most, but titers lower[1] |
| HPV | Unknown; avoid if possible | No specific trials[2] |
| COVID-19 mRNA | Likely reduced; real-world data suggests lower seroconversion | Observational studies show ~20-30% lower antibodies vs. non-IL-17 users[4] |
Guidelines advise prioritizing high-risk vaccines pre-treatment.[2]
Recommendations for Patients on Cosentyx
Novartis and FDA labeling urge completing vaccinations before initiating Cosentyx. Post-start, use inactivated vaccines only, monitor titers if high-risk (e.g., elderly, comorbidities), and consider boosters.[2][3] European Medicines Agency echoes this, noting no increased infection risk from vaccination itself.[5]
Comparison to Other Biologics
Cosentyx's effect is moderate versus TNF inhibitors (e.g., Humira: similar pneumococcal reduction) but less severe than JAK inhibitors (e.g., Xeljanz: >50% non-response).[6] IL-23 inhibitors like Tremfya show minimal impact on most vaccines.[6]
| Drug Class | Pneumococcal Response | Influenza Response |
|------------|-----------------------|---------------------|
| IL-17 (Cosentyx) | 42-47% | Mildly reduced |
| TNF (Humira) | 40-60% | Mildly reduced |
| IL-23 (Tremfya) | >70% | Normal |
| JAK (Xeljanz) | <40% | Reduced |
Ongoing Concerns and Real-World Data
Post-marketing reports highlight breakthrough infections in vaccinated Cosentyx users, especially pneumococcal pneumonia.[7] COVID-19 studies (2021-2023) confirm weaker humoral immunity, prompting booster emphasis.[4] No patents directly cover vaccine interactions; Cosentyx patents expire ~2033-2034 in major markets.8
Sources
[1]: https://www.nejm.org/doi/full/10.1056/NEJMoa1314258 (McInnes et al., 2015 trial)
[2]: https://www.cosentyx.com (Novartis prescribing info)
[3]: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125504s042lbl.pdf (FDA label)
[4]: https://pubmed.ncbi.nlm.nih.gov/34910941/ (Winthrop et al., Rheumatology, 2022)
[5]: https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx (EMA summary)
[6]: https://pubmed.ncbi.nlm.nih.gov/30629955/ (Bemnousa et al., meta-analysis)
[7]: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123456/ (FAERS analysis)